MedTrace Logo

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

NCT06594991 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

Conditions

Interventions

DRUG

Fianlimab

Fianlimab IV given every three weeks

DRUG

Cemiplimab

Cemiplimab IV given every three weeks

DRUG

Ipilimumab

Ipilimumab will be give every 6 weeks continuously

Sponsors & Collaborators

Principal Investigators

  • James Smithy, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-10
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06594991 on ClinicalTrials.gov